InMed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	4.51	4.94	4.6	4.14	1.09	-
Revenue Growth (YoY)	-6.73%	7.50%	11.18%	279.61%	-	-
Cost of Revenue	3.17	3.24	3.5	2.73	0.55	-
Gross Profit	1.34	1.71	1.1	1.4	0.54	-
Selling, General & Admin	6.5	6.56	5.8	5.85	6.67	4.48
Research & Development	2.47	2.85	3.22	3.73	7.28	5.34
Operating Expenses	9.18	9.62	9.24	9.78	14.14	9.94
Operating Income	-7.84	-7.92	-8.13	-8.38	-13.59	-9.94
Interest Expense	-0.02	-0.37	-	-	-	-
Interest & Investment Income	0.24	0.16	0.53	0.49	0.1	0.02
Currency Exchange Gain (Loss)	-0.04	-0.03	-0.06	-0.05	-0.12	-0.16
Other Non Operating Income (Expenses)	-	-	-	-	-	-0.12
EBT Excluding Unusual Items	-7.66	-8.16	-7.67	-7.93	-13.61	-10.2
Merger & Restructuring Charges	-	-	-	-	-0.2	-
Impairment of Goodwill	-	-	-	-	-2.02	-
Asset Writedown	-	-	-	-	-1.45	-
Other Unusual Items	-	-	-	-	-1.31	-
Pretax Income	-7.66	-8.16	-7.67	-7.93	-18.6	-10.2
Income Tax Expense	-	-	0.01	0.01	-	-
Net Income	-7.66	-8.16	-7.68	-7.95	-18.6	-10.2
Net Income to Common	-7.66	-8.16	-7.68	-7.95	-18.6	-10.2
Shares Outstanding (Basic)	3	1	0	0	0	0
Shares Outstanding (Diluted)	3	1	0	0	0	0
Shares Change (YoY)	391.70%	156.13%	211.26%	336.59%	108.64%	28.72%
EPS (Basic)	-2.73	-8.36	-20.14	-64.92	-663.32	-759.16
EPS (Diluted)	-2.73	-8.36	-20.14	-64.92	-663.32	-759.16
Free Cash Flow	-7.42	-7.77	-7	-7.45	-15.62	-9.79
Free Cash Flow Per Share	-2.65	-7.96	-18.36	-60.81	-557.14	-728.60
Gross Margin	29.73%	34.53%	23.95%	33.93%	49.89%	-
Operating Margin	-174.01%	-160.20%	-176.92%	-202.60%	-1247.60%	-
Profit Margin	-170.07%	-165.14%	-166.94%	-192.18%	-1707.32%	-
Free Cash Flow Margin	-164.69%	-157.14%	-152.14%	-180.02%	-1434.03%	-
EBITDA	-7.63	-7.71	-7.91	-8.18	-13.41	-9.82
EBITDA Margin	-169.32%	-155.89%	-172.15%	-197.71%	-	-
D&A For EBITDA	0.21	0.21	0.22	0.2	0.19	0.12
EBIT	-7.84	-7.92	-8.13	-8.38	-13.59	-9.94
EBIT Margin	-174.01%	-160.20%	-176.92%	-202.60%	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q